Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 7 recruiting now full pipeline

Bleeding: full-pipeline trial registry

7 of 24 indexed Bleeding trials are currently recruiting.

Corpus placement: #686 of 28,707 conditions by registered trial count.

24 US clinical trials · 7 currently recruiting · #686 of 28,707 conditions by registered trial count

Bleeding: 24 US clinical trials tracked, 7 recruiting.

Bleeding is the subject of 24 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 6 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is Boston Scientific Corporation, running 3 of these trials.

Enrollment posture brief

Registry condition bleeding

OPEN 7 | RECR 29% | LATE 6 | EARLY 4 | RANK #686 | SPON 3

Nearest open-share peer: Dyspnea (29% recruiting · 24 trials)

Aplastic Anemia37.5%Behavior37.5%Bleeding (this)29%Allergic Rhinitis8.3%Adult Acute Myeloid Leukemia0%
Open-enrollment share among volume-matched conditions near Bleeding

Bleeding lists 7 open slots (29% of 24 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Bleeding on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Bleeding is recruiting below its size-band peers.

    7 of 24 indexed trials (29.2%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Bleeding trials is spread across many organizations.

    Boston Scientific Corporation accounts for 3 of 24 trials (12.5%). 20 distinct sponsors appear on at least one study for this condition label.

  3. Typical Bleeding enrolment sits around 236 participants.

    Median target enrolment is 236 among the 24 trials that report a genuine target (sentinel values excluded). 5 of those (20.8%) plan for fewer than 100 participants.

  4. Bleeding research is mostly interventional.

    17 interventional and 7 observational studies make up this index (70.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 23Phase 32Phase 44

Open and recent trials

24 total, page 1 of 1

RECRUITING Phase 3 3,200 participants

Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG

Icahn School of Medicine at Mount Sinai

NCT04045665

RECRUITING NA 666 participants

Quantra Point-of-Care Hemostasis Monitoring

The Cleveland Clinic

NCT06328647

RECRUITING Phase 2 394 participants

Preoperative Tranexamic Acid (TXA) to Prevent Bleeding in Patients Undergoing Major Colorectal Surgery

Kristen Ban

NCT06657924

RECRUITING 250 participants

The Neonatal Hemorrhagic Risk Assessment in Thrombocytopenia

Karolinska Institutet

NCT04598750

RECRUITING Phase 2 140 participants

Factor VIII Inhibitor Bypass Activity (FEIBA) Versus Fresh Frozen Plasma As First Line Therapy For Bleeding After Cardiac Surgery

Northwell Health

NCT07032792

RECRUITING Phase 4 128 participants

Aspirin and Hemocompatibility Events in Chronic Advanced Heart Failure Patients With Assist Device

Columbia University

NCT06655376

RECRUITING 40 participants

Impact of IV Iron on Bleeding Symptoms in Iron Deficient Patients With Inherited Bleeding Disorders

Nicoletta C Machin

NCT07083583

ACTIVE NOT RECRUITING 19,114 participants

Aspirin in Reducing Events in the Elderly-Extension (ASPREE-XT)

Anne Murray

NCT07224347

ACTIVE NOT RECRUITING NA 3,000 participants

CHAMPION-AF Clinical Trial

Boston Scientific Corporation

NCT04394546

ACTIVE NOT RECRUITING NA 2,650 participants

Amplatzer Amulet LAAO vs. NOAC

Abbott Medical Devices

NCT04226547

ACTIVE NOT RECRUITING NA 1,857 participants

SIMPLAAFY Clinical Trial

Boston Scientific Corporation

NCT06521463

ACTIVE NOT RECRUITING 610 participants

Amulet™ ADVANCE LAA

Abbott Medical Devices

NCT05997446

COMPLETED NA 561 participants

LEAVE Safe With DOACs

University of Massachusetts, Worcester

NCT04068727

COMPLETED NA 411 participants

Deep Vein Thrombosis (DVT) Prevention in Total Hip Arthroplasty: Continuous Enhanced Circulation Therapy (CECT) Versus Low Molecular Weight Heparin (LMWH)

Medical Compression Systems

NCT00358735

COMPLETED NA 236 participants

Efficacy and Safety of HemoStyp as an Adjunct for Management of Secondary Hemostasis in the Operative Setting

United Health Products

NCT03654560

COMPLETED Phase 4 208 participants

Transfusion of Pathogen Reduced Cryoprecipitated Fibrinogen to Expedite Product Availability in Perioperative Bleeding

Weill Medical College of Cornell University

NCT05711524

COMPLETED 125 participants

Obsidio™ Conformable Embolic Registry

Boston Scientific Corporation

NCT06170619

COMPLETED Phase 4 109 participants

Treatment of Unfavorable Bleeding Patterns in Contraceptive Implant Users

Oregon Health and Science University

NCT02903121

COMPLETED Phase 2 108 participants

A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects

Portola Pharmaceuticals

NCT03310021

COMPLETED Phase 4 106 participants

PCC vs. FFP for Post Cardiopulmonary Bypass Coagulopathy and Bleeding

Mayo Clinic

NCT02557672

COMPLETED 85 participants

Peri-device Leakage Closure After LAAO

Cardiovascular Center Frankfurt

NCT04590898

COMPLETED Phase 3 80 participants

A Study in Older Subject to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Rivaroxaban

Portola Pharmaceuticals

NCT02220725

COMPLETED Phase 1 40 participants

PK, Safety Study of 90-Day Use of Vaginal Rings Containing Dapivirine and Levonorgestrel

International Partnership for Microbicides

NCT05041699

COMPLETED 33 participants

Thromboelastography in Non-elective Cesarean Delivery

Stanford University

NCT01514591

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 3
Phase 3 2
Phase 4 4

Named interventions

Most-linked intervention names on Bleeding records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
2 trials
IPM Ring-106 Combination
1 trials
IPM Ring-105 Combination
1 trials
Pathogen-Reduced Cryoprecipitate Biological
1 trials
Traditional Cryoprecipitate Biological
1 trials
Surgicel Device
1 trials
HemoStyp Device
1 trials
Fresh frozen plasma (FFP) Biological
1 trials

US sites by state

Facility locations filed on Bleeding trials. A trial with sites in several states counts in each.

California 11 trials
New York 6 trials
Arizona 6 trials
Texas 5 trials
Minnesota 5 trials
Arkansas 5 trials
Pennsylvania 4 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Bleeding page

24 registered trials, 7 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Bleeding condition card totals 24 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.